BMY Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
13.0B
+12.9%
11.5B
-8.1%
12.5B
+2.3%
12.2B
-0.4%
12.3B
Cost of Revenue
3.7B
+8.9%
3.4B
-16.5%
4.1B
+19.3%
3.4B
+1.9%
3.4B
Gross Profit
9.2B
+14.6%
8.1B
-4.0%
8.4B
-4.3%
8.8B
-1.2%
8.9B
Operating Expenses
5.2B
+8.9%
4.8B
-31.3%
7.0B
+20.8%
5.8B
-12.8%
6.6B
R&D
3.0B
+7.9%
2.7B
-31.1%
4.0B
+25.9%
3.2B
+22.5%
2.6B
SG&A
1.8B
+12.9%
1.6B
-25.9%
2.2B
+21.9%
1.8B
+4.4%
1.7B
Operating Income
4.0B
+23.1%
3.3B
+130.5%
1.4B
-52.8%
3.0B
+32.7%
2.3B
EBITDA
4.6B
+19.5%
3.9B
+61.3%
2.4B
-40.4%
4.0B
-16.1%
4.8B
Net Income
3.3B
+23.8%
2.7B
+146.7%
1.1B
-50.5%
2.2B
+67.2%
1.3B
EPS (Basic)
$1.62
+23.7%
$1.31
+147.2%
$0.53
-50.9%
$1.08
+68.8%
$0.64
EPS (Diluted)
$1.62
+23.7%
$1.31
+147.2%
$0.53
-50.9%
$1.08
+68.8%
$0.64
Shares (Diluted)
2.0B
+0.0%
2.0B
+0.4%
2.0B
+0.0%
2.0B
+0.0%
2.0B
Bristol-Myers Squibb (BMY) โ€” Financials